scholarly journals A Blood Pressure Lowering Effect Only through Complex Korean Medical Treatment, without Antihypertensive Drugs, for Patients with Stress Induced Hypertension - A Case Report

2021 ◽  
Vol 42 (5) ◽  
pp. 808-819
Author(s):  
Ji-hyun Lee ◽  
Min-yeong Roh ◽  
Seok-yeong Yoon ◽  
Hyung-sun Jun ◽  
Yang-hee Han ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Medical Treatment ◽  
Antihypertensive Drugs ◽  
Blood Pressure Lowering Effect ◽  
Hypertensive Patients ◽  
Pittsburg Sleep Quality Index ◽  
Induced Hypertension ◽  
Pressure Lowering ◽  
Pressure Symptom

Objectives: This study considered the effectiveness of integrative Korean medical treatment for stress-induced hypertensive patients without the use of conventional medication.Methods: A 62-year-old female with stress-induced hypertension (HTN) was hospitalized for 33 days. Her pattern identification was ascendant hyperactivity of liver yang (Ganyangsanghang)-type HTN. Herbal medicine and acupuncture were used for the treatment: Cheonggansoyo-san for 33 days and Chunwangbosim-dan for 15 days, together with acupuncture for 20 minutes twice a day. Blood pressure was checked daily during hospitalization with a digital sphygmomanometer in the brachial artery.Results: After 33 days of treatment, blood pressure decreased. The Handicap Inventory (DHI) scale and Pittsburg Sleep Quality Index (PSQI) scores both decreased. The patient also reported fewer complaints. A five-month follow-up after discharge, with no further treatment, confirmed stable blood pressure. Symptom improvements continued with no significant side effects.Conclusions: This study indicates that Korean medical treatment is effective for stress-induced hypertensive patients.

scholarly journals Nebivolol - A Review

1970 ◽  
Vol 6 (2) ◽  
pp. 93-96
Author(s):  
Uzzal Kanti Das ◽  
Syed Ali Ahsan ◽  
Mohammad Salman ◽  
Mohammad Ferdous Ur Rahaman ◽  
Md Mizanur Rahman Khan ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Blood Pressure ◽  
Arterial Stiffness ◽  
Antihypertensive Drugs ◽  
Peripheral Resistance ◽  
Blood Pressure Lowering Effect ◽  
Pressure Lowering ◽  
Β Blocker ◽  
General Response ◽  
Adrenergic Blocking

Nebivolol is a vasodilating β-blocker, which can be distinguished from other β-blockers by its haemodynamic profile. It combines β-adrenergic blocking activity with a vasodilating effect mediated by the endothelial Larginine nitric oxide (NO) pathway. The blood pressure lowering effect of nebivolol is linked to a reduction in peripheral resistance and an increase in stroke volume and preservation of cardiac output. Clinical trials have demonstrated that nebivolol reduces blood pressure similarly to atenolol, bisoprolol, amlodipine, nifedipine, lisinopril, and hydrochlorothiazide. The tolerability of nebivolol is similar to or better than that of these agents. In general, response rates to treatment are higher and the frequency and severity of adverse events are either comparable or lower with nebivolol. Endothelium-derived NO is important in the regulation of large arterial stiffness, which in turn is a major risk factor for cardiovascular disease. Therefore, antihypertensive drugs, such as nebivolol, that also improve endothelial function and decrease arterial stiffness, may contribute to a reduction in cardiovascular risk.Key words: Vasodilating β-blocker; nitric oxide (NO); peripheral resistance; arterial stiffness DOI: 10.3329/uhj.v6i2.7254University Heart Journal Vol. 6, No. 2, July 2010 pp.93-96

Abstract 4889: Long-term Changes Of Left Ventricular (lv) Structure And Function After Adrenalectomy Or Medical Treatment For Primary Aldosteronism

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Gian Paolo Rossi ◽  
Maurizio Cesari ◽  
Maria Teresa Seccia ◽  
Gisella Pitter ◽  
Achille Cesare Pessina
Keyword(s):  
Blood Pressure ◽  
Medical Treatment ◽  
Wall Thickness ◽  
Primary Aldosteronism ◽  
Antihypertensive Drugs ◽  
Statistical Significance ◽  
Left Ventricular ◽  
Diastolic Filling ◽  
Lv Mass

Objectives: to evaluate the structural and functional LV outcome of surgically or medically treated patients with documented primary aldosteronism (PA). Methods: after a cross-sectional Doppler echocardiography assessment of LV wall thickness and dimensions and transmitral LV filling flow velocity indexes, 55 PA patients entered a prospective follow-up study lasting 6.4 years (range: 4.5 to 8 years) after adrenalectomy (n=41) or medical treatment (n=14). The diagnosis of aldosterone producing adenoma (APA) and idiopathic hyperaldosteronism (IHA) was based on adrenal vein sampling, pathology, and on follow-up data. Results: by the PAPY Study criteria 47 patients had APA and 8 IHA. Excess LV hypertrophy (LVH) and concentric remodelling rate was observed at baseline in both groups; atrial contribution to LF filling (ACLVF) was higher in the 14 (6 APA and 8 IHA) medically treated than in the 41 adrenalectomized patients. At follow-up blood pressure (p<0.001) and the rate of LVH decreased (p<0.001): LV mass index (MI) fell (from 115±22 to 106±18 in adrenalectomized patients and from, 118±26 to 103±21 in medically treated patients). This LVMI reduction and an increase of relative wall thickness (from 0.43±0.07 to 0.46±0.06 in adrenalectomized patients and from 0.41±0.06 to 0.45±0.05 in medically treated patients) attained statistical significance only in the former. By contrast, the reduction of ACLVF was significant only in the latter (p=0.002), thus indicating a normalization of the LV diastolic filling indexes (but only in the medically-treated patients which showed an impaired diastolic function at baseline). Conclusion: 1) Both treatments reduce BP, LV mass index and the prevalence of LVH; 2) With a similar fall of blood pressure and despite a greater reduction of antihypertensive drugs, these changes were more prominent in adrenalectomized patients; 3) An improvement of LV diastolic filling occurs also in the medically-treated PA patients when it is altered at baseline.

scholarly journals Treatment of hypertension with a very low dose of antibody to C-fragment of type 1 angiotensin II receptor

2008 ◽  
Vol 14 (3) ◽  
pp. 236-238
Author(s):  
V. Petrov ◽  
A. Kolosova ◽  
S. Tarasov ◽  
L. V . Sabanov ◽  
M. V. Kachanova ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Low Dose ◽  
Blood Pressure Lowering ◽  
Angiotensin Ii Receptor ◽  
Blood Pressure Lowering Effect ◽  
Night Time ◽  
Hypertensive Patients ◽  
Treatment Of Hypertension ◽  
Pressure Lowering

The study documented blood pressure lowering effect according to ABMP data in 50 hypertensive patients receiving antibodies to C-end fragment to AT1 receptors for 3 months. (Cardos). The drug was well-tolerated and showeed 24-hour significant decrease of blood pressure at day-time as well as at night-time.

Sign in / Sign up

Export Citation Format

Share Document